Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) fell 7.5% during mid-day trading on Wednesday . The company traded as low as $4.90 and last traded at $4.90. 1,174 shares were traded during trading, a decline of 85% from the average session volume of 7,832 shares. The stock had previously closed at $5.30.
Pasithea Therapeutics Stock Performance
The stock has a fifty day simple moving average of $6.26 and a 200-day simple moving average of $6.92.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($3.70) earnings per share (EPS) for the quarter.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Recommended Stories
- Five stocks we like better than Pasithea Therapeutics
- What is a SEC Filing?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- 3 Healthcare Dividend Stocks to Buy
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Consumer Discretionary Stocks Explained
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
